| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:42 UTC |
|---|
| HMDB ID | HMDB0014683 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Amoxapine |
|---|
| Description | Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. |
|---|
| Structure | ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1 InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2 |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Chloro-11-(1-piperazinyl)dibenz(b,F)(1,4)oxazepine | ChEBI | | Amoxapina | ChEBI | | Amoxapinum | ChEBI | | Desmethylloxapin | ChEBI | | Asendin | Kegg | | Amoxepine | HMDB | | Amoxapine lederle brand | HMDB | | Défanyl | HMDB | | Cyanamid brand OF amoxapine | HMDB | | Amoxapine wyeth brand | HMDB | | Asendis | HMDB | | Desmethylloxapine | HMDB | | Amoxapine cyanamid brand | HMDB | | Demolox | HMDB | | Lederle brand OF amoxapine | HMDB | | Wyeth brand OF amoxapine | HMDB |
|
|---|
| Chemical Formula | C17H16ClN3O |
|---|
| Average Molecular Weight | 313.781 |
|---|
| Monoisotopic Molecular Weight | 313.098189856 |
|---|
| IUPAC Name | 13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene |
|---|
| Traditional Name | amoxapine |
|---|
| CAS Registry Number | 14028-44-5 |
|---|
| SMILES | ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2 |
|---|
| InChI Key | QWGDMFLQWFTERH-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dibenzoxazepines. Dibenzoxazepines are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzoxazepines |
|---|
| Sub Class | Dibenzoxazepines |
|---|
| Direct Parent | Dibenzoxazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dibenzoxazepine
- Diaryl ether
- Aryl chloride
- Aryl halide
- 1,4-diazinane
- Piperazine
- Imidolactam
- Benzenoid
- Amidine
- Carboxylic acid amidine
- Secondary aliphatic amine
- Oxacycle
- Ether
- Azacycle
- Secondary amine
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic nitrogen compound
- Organic oxygen compound
- Organohalogen compound
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Amine
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 175.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.17 g/L | Not Available | | LogP | 3.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.67 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.3105 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.91 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 131.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 925.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 247.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 135.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 183.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 99.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 325.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 361.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 499.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 772.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 301.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 822.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 211.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 291.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 372.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 284.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 23.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Amoxapine,1TMS,isomer #1 | C[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 2899.7 | Semi standard non polar | 33892256 | | Amoxapine,1TMS,isomer #1 | C[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 2748.2 | Standard non polar | 33892256 | | Amoxapine,1TMS,isomer #1 | C[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 4154.0 | Standard polar | 33892256 | | Amoxapine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 3119.5 | Semi standard non polar | 33892256 | | Amoxapine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 2939.5 | Standard non polar | 33892256 | | Amoxapine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1CCN(C2=NC3=CC=CC=C3OC3=CC=C(Cl)C=C23)CC1 | 4334.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Amoxapine GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-6190000000-1acb98762576326ae75b | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Amoxapine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Amoxapine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-052b-4490000000-6bbd0d2c0c8fe332c636 | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine LC-ESI-qTof , Positive-QTOF | splash10-00dl-2690000000-0e598ca107ca857b8f06 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine , positive-QTOF | splash10-044i-0169000000-d1665f2e6d27a9efaa39 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine , positive-QTOF | splash10-002f-0940000000-9bf5c13f1f2b9b04f465 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine , positive-QTOF | splash10-00dl-2690000000-0e598ca107ca857b8f06 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 75V, Positive-QTOF | splash10-006x-2950000000-2fb725746001d0be41d1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 90V, Positive-QTOF | splash10-0006-0910000000-7df25fea8ffb96c66d50 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 30V, Positive-QTOF | splash10-03k9-1059000000-99ec364d324293ba9191 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 15V, Positive-QTOF | splash10-03di-0009000000-fb09780a1d33ba8eb3c8 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 45V, Positive-QTOF | splash10-00di-2090000000-046bbbcb38472a6b5a4c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 60V, Positive-QTOF | splash10-00di-2290000000-47774f87a43619d76d34 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Amoxapine 60V, Positive-QTOF | splash10-00di-2290000000-53b12cd961449d9ea634 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 10V, Positive-QTOF | splash10-03di-0009000000-873be01dd22731e1f7a7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 20V, Positive-QTOF | splash10-03di-0049000000-3989b74ad41770f20ee0 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 40V, Positive-QTOF | splash10-01r6-9440000000-54259557a6e11d912eb7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 10V, Negative-QTOF | splash10-03di-0019000000-eaaa73a51b5bbc0bf28b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 20V, Negative-QTOF | splash10-03di-0049000000-be3ce6855a4cc094b8fc | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 40V, Negative-QTOF | splash10-0006-9250000000-d2f001cf68189e0c19d4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 10V, Negative-QTOF | splash10-03di-0009000000-c66d97d82d39ee90b585 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 20V, Negative-QTOF | splash10-03di-0009000000-d2c945077b93a0423349 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 40V, Negative-QTOF | splash10-00e9-4091000000-4a8bdcd3ca72bcad379c | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 10V, Positive-QTOF | splash10-03di-0009000000-06ad1e364d70213564e8 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 20V, Positive-QTOF | splash10-03di-0039000000-17396abffdd86c9873e9 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amoxapine 40V, Positive-QTOF | splash10-05e9-1291000000-4d8a424af3692977794b | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|